BioGend Therapeutics Co., Ltd. (TPEX: 6733)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
32.85
-0.15 (-0.45%)
Dec 20, 2024, 1:30 PM CST
-12.52%
Market Cap 4.08B
Revenue (ttm) 156.64M
Net Income (ttm) -109.93M
Shares Out 124.26M
EPS (ttm) -0.89
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 103,212
Open 34.45
Previous Close 33.00
Day's Range 32.55 - 34.45
52-Week Range 31.40 - 42.30
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Mar 3, 2025

About BioGend Therapeutics

BioGend Therapeutics Co., Ltd. develops regenerative bio-orthopaedic products. It is developing BiG-001 and BiG-006, an osteoinductive bone graft substitute; and BiG-009, an autologous cartilage repair system. The company was founded in 2016 and is based in Taipei, Taiwan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6733
Full Company Profile

Financial Performance

In 2023, BioGend Therapeutics's revenue was 109.91 million, an increase of 249.51% compared to the previous year's 31.45 million. Losses were -156.33 million, -15.25% less than in 2022.

Financial Statements

News

There is no news available yet.